MX370645B - Agonistas npr-b novedosos. - Google Patents

Agonistas npr-b novedosos.

Info

Publication number
MX370645B
MX370645B MX2017012681A MX2017012681A MX370645B MX 370645 B MX370645 B MX 370645B MX 2017012681 A MX2017012681 A MX 2017012681A MX 2017012681 A MX2017012681 A MX 2017012681A MX 370645 B MX370645 B MX 370645B
Authority
MX
Mexico
Prior art keywords
agonists
npr
novel npr
novel
unconventional
Prior art date
Application number
MX2017012681A
Other languages
English (en)
Inventor
Osterkamp Frank
Hawlisch Heiko
Hummel Gerd
Knaute Tobias
Reimer Ulf
Reineke Ulrich
Richter Uwe
Simon Bernadett
Specker Edgar
Woischnik Markus
R Hellberg Mark
Original Assignee
Shire Orphan Therapies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43781057&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX370645(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Orphan Therapies Gmbh filed Critical Shire Orphan Therapies Gmbh
Publication of MX370645B publication Critical patent/MX370645B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a compuestos novedosos que tienen actividad agonista de NPR-B. Los compuestos preferidos son péptidos lineales que contienen de 8-13 residuos de L o D-aminoácidos convencionales o no convencionales conectados entre sí mediante enlaces de péptido.
MX2017012681A 2009-09-25 2010-09-23 Agonistas npr-b novedosos. MX370645B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24596009P 2009-09-25 2009-09-25
PCT/US2010/049912 WO2011038061A2 (en) 2009-09-25 2010-09-23 Novel npr-b agonists

Publications (1)

Publication Number Publication Date
MX370645B true MX370645B (es) 2019-12-19

Family

ID=43781057

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2014001528A MX354005B (es) 2009-09-25 2010-09-23 Agonistas npr-b novedosos.
MX2012003398A MX2012003398A (es) 2009-09-25 2010-09-23 Agonistas npr-b novedosos.
MX2017012681A MX370645B (es) 2009-09-25 2010-09-23 Agonistas npr-b novedosos.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2014001528A MX354005B (es) 2009-09-25 2010-09-23 Agonistas npr-b novedosos.
MX2012003398A MX2012003398A (es) 2009-09-25 2010-09-23 Agonistas npr-b novedosos.

Country Status (17)

Country Link
US (5) US8546523B2 (es)
EP (1) EP2480247B1 (es)
JP (3) JP5893561B2 (es)
KR (3) KR20180049198A (es)
CN (2) CN102548574B (es)
AR (1) AR078445A1 (es)
AU (1) AU2010298256B2 (es)
BR (1) BR112012006579A2 (es)
CA (1) CA2773949C (es)
CL (2) CL2012000715A1 (es)
MX (3) MX354005B (es)
PH (1) PH12012500562A1 (es)
RU (3) RU2636738C2 (es)
TW (2) TWI625126B (es)
UY (1) UY32902A (es)
WO (1) WO2011038061A2 (es)
ZA (3) ZA201201630B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2510942B1 (en) 2005-04-07 2015-09-02 Cardiorentis AG Use of natriuretic peptide for treating heart failure
ES2507553T3 (es) * 2006-08-02 2014-10-15 Johannes Gutenberg-Universität Mainz Fármaco contra intoxicaciones por LCT
MX354005B (es) * 2009-09-25 2018-02-08 Shire Orphan Therapies Gmbh Agonistas npr-b novedosos.
AR078446A1 (es) 2009-12-18 2011-11-09 Alcon Res Ltd Agonistas de npr-b. uso.
CN108653715A (zh) * 2011-12-16 2018-10-16 卡乐斯治疗公司 用于治疗视网膜病症和疾病的anp、bnp以及cnp相关肽及其衍生物的方法和用途
EA201500765A1 (ru) * 2013-01-25 2015-12-30 Кардиорентис Лтд. Способы лечения сердечно-сосудистых заболеваний
LT3464336T (lt) 2016-06-01 2022-05-10 Athira Pharma, Inc. Junginiai
WO2018144742A1 (en) 2017-02-01 2018-08-09 Shire Human Genetic Therapies, Inc. Compounds and compositions for the treatment of ophthalmic disorders
CN112566622A (zh) * 2018-06-19 2021-03-26 细胞疗法有限责任公司 用于治疗青光眼或高眼压症的包含眼内压降低剂、cnp化合物、npr-b化合物、tie-2激动剂或神经营养剂的缓释药物递送系统
ES3034676T3 (en) * 2018-11-16 2025-08-21 Arcus Biosciences Inc Inhibitors of arg1 and/or arg2
AU2021288219A1 (en) * 2020-06-12 2023-02-02 Pharmain Corporation C-type natriuretic peptides and methods thereof in treating acute lung injury
KR102677730B1 (ko) * 2023-03-27 2024-06-27 나인바이오팜 주식회사 지방 분해 효능을 갖는 펩타이드 및 이의 용도

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757048A (en) 1985-11-05 1988-07-12 Biotechnology Research Associates J.V. Synthetic analogs of atrial natriuretic peptides
EP0323740A3 (en) * 1987-12-24 1990-12-12 California Biotechnology, Inc. Linear analogs of atrial natriuretic peptides
WO1990001940A1 (en) * 1988-08-18 1990-03-08 California Biotechnology Inc. Atrial natriuretic peptide clearance inhibitors
CA2345414A1 (en) 1998-09-28 2000-04-06 Santen Pharmaceutical Co., Ltd. Eyedrops for promoting lacrimal secretion or treating keratoconjunctival disorders containing natriuretic peptide as active ingredient
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
ATE496060T1 (de) 2004-07-15 2011-02-15 Univ Queensland Proteinartige verbindungen und anwendungen davon
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US20090035287A1 (en) * 2005-09-26 2009-02-05 Zurit Levine Atrial natriuretic peptide (anp) splice variants and methods of using same
JP2009511060A (ja) * 2005-10-14 2009-03-19 バイオレクシス ファーマシューティカル コーポレーション ナトリウム利尿ペプチド修飾されたトランスフェリン融合タンパク質
KR101434612B1 (ko) * 2006-03-30 2014-08-26 팔라틴 테크놀로지스 인코포레이티드 사이클릭 나트륨 이뇨 펩타이드 구조물
US7795221B2 (en) * 2006-03-30 2010-09-14 Palatin Technologies, Inc. Linear natriuretic peptide constructs
AU2008326327A1 (en) * 2007-11-21 2009-05-28 Biomarin Pharmaceutical Inc. Variants of C-type natriuretic peptide
WO2011038066A2 (en) 2009-09-25 2011-03-31 Alcon Research, Ltd. Novel npr-b agonists
MX354005B (es) * 2009-09-25 2018-02-08 Shire Orphan Therapies Gmbh Agonistas npr-b novedosos.
AR078446A1 (es) 2009-12-18 2011-11-09 Alcon Res Ltd Agonistas de npr-b. uso.

Also Published As

Publication number Publication date
EP2480247A2 (en) 2012-08-01
CN105732767A (zh) 2016-07-06
MX354005B (es) 2018-02-08
EP2480247A4 (en) 2013-09-04
KR20120091110A (ko) 2012-08-17
TWI625126B (zh) 2018-06-01
UY32902A (es) 2011-02-28
CL2012000715A1 (es) 2012-11-30
RU2557290C2 (ru) 2015-07-20
AR078445A1 (es) 2011-11-09
JP2015131856A (ja) 2015-07-23
KR101854820B1 (ko) 2018-05-04
CA2773949A1 (en) 2011-03-31
KR20180049198A (ko) 2018-05-10
US9982016B2 (en) 2018-05-29
CN102548574B (zh) 2016-03-23
ZA201201630B (en) 2014-05-28
KR101768661B1 (ko) 2017-08-16
CL2017001190A1 (es) 2017-12-01
US20130345394A1 (en) 2013-12-26
TWI577384B (zh) 2017-04-11
TW201110974A (en) 2011-04-01
US20160194357A1 (en) 2016-07-07
ZA201401625B (en) 2018-08-25
ZA201702958B (en) 2018-08-29
US8546523B2 (en) 2013-10-01
AU2010298256B2 (en) 2015-08-13
JP5893561B2 (ja) 2016-03-23
US9169293B2 (en) 2015-10-27
CA2773949C (en) 2020-11-03
RU2012116531A (ru) 2013-10-27
KR20170094564A (ko) 2017-08-18
JP2017137362A (ja) 2017-08-10
US20110077381A1 (en) 2011-03-31
RU2015124607A (ru) 2015-12-10
MX2012003398A (es) 2012-04-10
US20170313743A1 (en) 2017-11-02
WO2011038061A2 (en) 2011-03-31
CN102548574A (zh) 2012-07-04
RU2017139870A3 (es) 2019-05-16
JP2013505937A (ja) 2013-02-21
EP2480247B1 (en) 2020-02-12
PH12012500562A1 (en) 2012-10-22
RU2017139870A (ru) 2019-05-16
AU2010298256A1 (en) 2012-04-12
JP6211032B2 (ja) 2017-10-11
RU2636738C2 (ru) 2017-11-28
WO2011038061A3 (en) 2011-07-28
US20180334477A1 (en) 2018-11-22
US9745344B2 (en) 2017-08-29
US10196423B2 (en) 2019-02-05
BR112012006579A2 (pt) 2016-11-22
TW201630619A (zh) 2016-09-01

Similar Documents

Publication Publication Date Title
MX370645B (es) Agonistas npr-b novedosos.
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
DOP2012000244A (es) Nuevos péptidos y métodos para su preparación y uso
MX2010004297A (es) Antagonistas de glucagon.
UA118167C2 (uk) Пептид та його застосування
CL2013003416A1 (es) Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa.
CR11511A (es) Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado
EP2185170A4 (en) COMPOSITION FOR PEPTIDE ANALOGUE WITH LONG-TERM EFFECT
MX366935B (es) Peptidos intestinales vasoactivos modificados.
PE20141672A1 (es) FORMULACION PARA ANTICUERPO ANTI-alfa4�7
EP2118122A4 (en) NOVEL ANTIMICROBIAL PEPTIDES
MA31997B1 (fr) Nouveaux derives de l'insuline presentant un profil d'action extremement retarde
NI201000114A (es) Nuevos derivados de insulina con perfil tiempo/acción extremadamente retardado.
ES2693321T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
MY151985A (en) Dental wipe
WO2013000922A9 (en) Ccr2 antagonist peptides
ATE404225T1 (de) Radiofluorierte peptide
CO7131365A2 (es) Factores de coagulación de acción prolongada y métodos de producción de los mismos
MX2018014023A (es) Compuestos de citocina inhibidora de macrofagos 1 (mic-1) y uso de estos.
MX2015002994A (es) Peptidos de inhibidores obtenidos del receptor desencadenante expresado en celulas mieloides de tipo 1 (trem-1) y transcrito similar a trem 1 (tlt-1) y usos de los mismos.
ES2570458T3 (es) Peptidomiméticos fijados sobre una matriz con actividad moduladora de CXCR7
MX2009013682A (es) Enlazador de fmoc polimerico hidrolizable.
IN2014DN09367A (es)
DK2207790T3 (da) Biologisk aktive C-terminalt argininholdige peptider
AR075933A1 (es) Composiciones polipeptidas y de inmunizacion conteniendo polipeptidos positivos gram y metodos de uso